Posts - Bill - HR 3520 STAND Against Emerging Opioids Act

house 05/20/2025 - 119th Congress

We are working to classify tianeptine as a Schedule III controlled substance to better regulate its use and address potential risks associated with this emerging opioid. This legislation aims to enhance public safety by bringing tianeptine under federal oversight.

HR 3520 - STAND Against Emerging Opioids Act

Views

moderate 05/20/2025

The devil’s in the details: I support scheduling, but Congress better keep an eye on how this affects patients and doctors.

right-leaning 05/20/2025

Cracking down on tianeptine sounds good, but is labeling another drug really the answer or just political grandstanding?

left-leaning 05/20/2025

This bill shows we can protect communities without criminalizing addiction—let’s keep pushing for compassionate care.

right-leaning 05/20/2025

More government meddling—when will Washington learn that people need freedom, not more red tape?

moderate 05/20/2025

Tianeptine’s shady side is real, but regulation needs to be precise, not just reactionary panic.

moderate 05/20/2025

Schedule it, but don’t overdo it—let’s make sure we’re solving problems, not creating new ones.

right-leaning 05/20/2025

Schedule it and watch the black market explode; prohibition never fixed anything, folks.

left-leaning 05/20/2025

Finally, a bill that puts public health over profits—about time we stand up to Big Pharma’s sketchy chemicals.

left-leaning 05/20/2025

Locking down emerging opioids like tianeptine is a small step toward ending the overdose epidemic, but we still need more social support.